Optia® continuous mononuclear collection (CMNC) system is a safe and efficient system for hematopoietic progenitor cells-apheresis (HPC-a) collection and yields a lower product hematocrit (HCT%) than the COBE® spectra system: A retrospective study.

PURPOSE:We evaluated the Optia® continuous mononuclear collection (CMNC) system for hematopoietic progenitor cell-apheresis (HPC-A) collection (Terumo BCT, Lakewood, CO) compared to the COBE® Spectra (Terumo BCT, Lakewood, CO), including both large volume leukapheresis (LVL) and non-LVL collections. METHODS:We performed a retrospective data analysis of all autologous HPC-A collections with the Optia® CMNC system (n = 93; LVL = 59, non-LVL = 34) since implementation at our institution and compared it with a similar number of concurrent collections utilizing the COBE® Spectra (n = 96; LVL = 68, non-LVL = 28). The population studied included multiple myeloma (62 patients/171 collections) and lymphoma (5 patients/18 collections). Mobilization was achieved using chemotherapy + G-CSF (n = 108), chemotherapy + G-CSF + plerixafor (n = 67), G-CSF alone (n = 10), or G-CSF + plerixafor (n = 4). Based on our minimum predicted collection formula and the collection goal, 7-30 L of whole blood was processed. Per protocol, a minimum of 2 days of collection was performed. RESULTS:HPC-A collected on Optia® CMNC had lower %HCT than those collected on COBE® Spectra (3.7 versus 4.3%, P = .029). There were no statistically significant differences between the two devices for other variables examined, including preapheresis WBC count and CD34+ cell count, procedure time, whole blood volume processed, collection efficiency (CE2), % platelet loss and throughput. CE2 for both devices was higher when <30 L of whole blood volume was processed. A linear correlation was noted between the preapheresis CD34+ cell count and CD34+ cells collected. No adverse events or bleeding episodes were noted, even when acetyl salicyclic acid (ASA) was given. CONCLUSIONS:Optia® CMNC system is equivalent to the COBE® Spectra, with significantly lower product HCT%.